Microvention AnEurysm & STroke Real-life Data cOllection
Spain1,000 participantsStarted 2024-12-30
Plain-language summary
The MAESTRO registry is a post-market, single-arm, non-interventional, multicenter registry
Who can participate
SexALL
See this in plain English?
AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.
Inclusion criteria:
* Patient, or another authorized person as per country-specific regulations, is informed of the data collection and gives non-opposition or consent prior to the data collection in accordance with institutional and geographic requirements.
* For Cohort 1, patient is treated for a ruptured or unruptured intracranial aneurysm using a commercially available MicroVention implant device as the primary treatment device and the decision to use this device has been made by the treating physician outside the context of the MAESTRO study.
* For Cohort 2, patient is treated using a commercially available MicroVention mechanical thrombectomy device as the first-line treatment strategy and the decision to use this device has been made by the treating physician outside the context of the MAESTRO study.
Note: For the purposes of this protocol, ancillary/accessory devices such as balloon catheters, carotid stent for extracranial stenosis and other access devices are not considered primary treatment devices. Further, devices used for rescue following attempt of a different primary treatment device are not considered initial primary treatment devices.
Exclusion Criteria:
* Patient is or is expected to be inaccessible for follow-up.
* Patient is participating or intends to participate in another study that changes the site practice.
* Patient is already participating in the MAESTRO study for the same pathology.
What they're measuring
1
Cohort 1: Proportion of aneurysms with complete occlusion
Timeframe: 18 (±6) months
2
Cohort 2: Proportion of patients achieving final mTICI ≥ 2b revascularization